The U.S. Supreme Court sounded as if it could be getting a case of buyer’s remorse over patent law’s on-sale bar.

The justices granted cert in Helsinn Healthcare v. Teva Pharmaceuticals last summer after the pharmaceutical industry argued that legislators clearly intended to change the definition of what is “on sale”—and therefore faces a one-year ticking clock to be patented—in the America Invents Act.